Abstract
The use of imiquimod in cervical intraepithelial lesions has been evaluated in different trials and was found associated with various and numerous adverse events. Telogen effluvium is an infrequent systemic adverse event observed mainly in patients experiencing severe systemic adverse reactions. This paper presents the case of a young woman who developed telogen effluvium after intravaginal imiquimod use that was not preceded by other systemic adverse events and resolved gradually after nine months. Telogen effluvium after intravaginal imiquimod use is rare, may appear without any preceding severe adverse event, and may persist for an extended period.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
